STOCK TITAN

Movano Health Announces Reverse Stock Split

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)

Movano Health (Nasdaq: MOVE) announced a 1-for-15 reverse stock split effective October 29, 2024. The split will reduce outstanding shares from approximately 99.5 million to 6.6 million, with the stock continuing to trade on Nasdaq under 'MOVE'. The reverse split aims to increase the bid price to meet Nasdaq's minimum requirements for continued listing. The measure was authorized by stockholders on July 9, 2024. Fractional shares will be rounded up to the next whole share, and proportionate adjustments will be made to equity plans. The company's transfer agent, Pacific Stock Transfer Company, will handle the exchange process.

Movano Health (Nasdaq: MOVE) ha annunciato un'operazione di raggruppamento azionario 1-per-15 che avrà effetto il 29 ottobre 2024. Questa operazione ridurrà il numero di azioni in circolazione da circa 99,5 milioni a 6,6 milioni, con le azioni che continueranno a essere negoziate su Nasdaq con il simbolo 'MOVE'. L'obiettivo del raggruppamento è aumentare il prezzo delle azioni per soddisfare i requisiti minimi di Nasdaq per la continuità della quotazione. La misura è stata autorizzata dagli azionisti il 9 luglio 2024. Le azioni frazionarie saranno arrotondate all'azione intera successiva e saranno effettuati aggiustamenti proporzionali ai piani azionari. L'agente di trasferimento della società, Pacific Stock Transfer Company, gestirà il processo di scambio.

Movano Health (Nasdaq: MOVE) anunció una división de acciones inversa de 1 por 15 que entrará en vigor el 29 de octubre de 2024. Esta división reducirá las acciones en circulación de aproximadamente 99.5 millones a 6.6 millones, con las acciones continuando a negociarse en Nasdaq bajo el símbolo 'MOVE'. La división inversa tiene como objetivo aumentar el precio de oferta para cumplir con los requisitos mínimos de Nasdaq para la cotización continua. La medida fue autorizada por los accionistas el 9 de julio de 2024. Las acciones fraccionarias se redondearán a la siguiente acción entera, y se harán ajustes proporcionales a los planes de capital. El agente de transferencias de la empresa, Pacific Stock Transfer Company, se encargará del proceso de intercambio.

모바노 헬스(Movano Health)(나스닥: MOVE)가 2024년 10월 29일부터 시행되는 1대 15의 역분할을 발표했습니다. 이 분할은 약 9,950만 주의 유통 주식을 660만 주로 줄이며, 주식은 계속해서 'MOVE'라는 이름으로 나스닥에서 거래됩니다. 역분할의 목적은 나스닥의 최소 상장 요건을 충족하기 위해 주가를 높이는 것입니다. 이 조치는 2024년 7월 9일 주주들에 의해 승인되었습니다. 분할 주식은 다음 전체 주식으로 반올림되며, 자본 계획에 비례 조정이 이루어질 것입니다. 회사의 이전 대리업체인 퍼시픽 스톡 트랜스퍼 컴퍼니가 교환 프로세스를 처리합니다.

Movano Health (Nasdaq: MOVE) a annoncé une opération de regroupement d'actions de 1 pour 15, effective le 29 octobre 2024. Ce regroupement réduira le nombre d'actions en circulation d'environ 99,5 millions à 6,6 millions, les actions continuant d'être négociées sur Nasdaq sous le symbole 'MOVE'. L'objectif du regroupement est d'augmenter le prix de l'offre pour répondre aux exigences minimales de Nasdaq pour le maintien de la cotation. La mesure a été autorisée par les actionnaires le 9 juillet 2024. Les actions fractionnaires seront arrondies à l'action entière suivante, et des ajustements proportionnels seront effectués pour les plans d'équité. L'agent de transfert de la société, Pacific Stock Transfer Company, s'occupera du processus d'échange.

Movano Health (Nasdaq: MOVE) hat einen 1-zu-15-Rücksplit bekannt gegeben, der am 29. Oktober 2024 in Kraft tritt. Der Split wird die ausstehenden Aktien von etwa 99,5 Millionen auf 6,6 Millionen reduzieren, wobei die Aktien weiterhin unter 'MOVE' an der Nasdaq gehandelt werden. Der Rücksplit zielt darauf ab, den Angebotspreis zu erhöhen, um die Mindestanforderungen der Nasdaq für eine Fortsetzung der Listung zu erfüllen. Die Maßnahme wurde am 9. Juli 2024 von den Aktionären genehmigt. Bruchstücke von Aktien werden auf die nächste ganze Aktie aufgerundet, und es werden proportionale Anpassungen an den Aktienplänen vorgenommen. Der Übertragungsagent des Unternehmens, die Pacific Stock Transfer Company, wird den Austauschprozess übernehmen.

Positive
  • None.
Negative
  • Implementation of reverse stock split indicates struggle to maintain Nasdaq listing requirements
  • Risk of potential delisting from Nasdaq due to low share price
  • Significant share consolidation (15:1 ratio) suggests serious price deterioration

Insights

This reverse stock split represents a significant technical adjustment but doesn't fundamentally change Movano Health's market value. The 1-for-15 split will reduce outstanding shares from 99.5 million to approximately 6.6 million, while proportionally increasing the stock price. This is primarily a compliance maneuver to meet Nasdaq's minimum bid price requirement and avoid potential delisting.

The timing and mechanics are straightforward - trading on split-adjusted basis begins October 29, with fractional shares rounded up. However, investors should note this is often viewed as a negative signal, typically undertaken by companies struggling with low share prices. While it doesn't directly impact the company's fundamentals or market cap, historical patterns show that reverse splits can precede further price declines if the underlying business challenges aren't addressed.

Shares Expected to Begin Trading on Split-Adjusted Basis on October 29, 2024

PLEASANTON, Calif., Oct. 25, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced today that it will implement a 1-for-15 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on October 29, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, October 29, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol "MOVE." The new CUSIP number for the common stock will be 62459M 206.

The Reverse Stock Split is intended to increase the bid price of the common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company's stockholders authorized the reverse stock split at the Company's annual meeting of stockholders held on July 9, 2024, with the final ratio subsequently determined by the Company's Board of Directors.

As a result of the Reverse Stock Split, every 15 shares of the Company's pre-split common stock issued and outstanding will be automatically reclassified into one new share of the Company's common stock. This will reduce the number of shares outstanding from approximately 99.5 million shares to approximately 6.6 million shares. The number of authorized shares of the Company's common stock will remain unchanged. Stockholders who would otherwise be entitled to receive a fractional share will instead automatically have their fractional interests rounded up to the next whole share, after aggregating all the fractional interests of a holder resulting from the Reverse Stock Split. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company's equity plans and grants thereunder, as applicable. The Reverse Stock Split will not affect the par value of the common stock.

The combination of, and reduction in, the issued shares of common stock as a result of the Reverse Stock Split will occur automatically at the effective time of the Reverse Stock Split without any additional action on the part of the Company's stockholders. The Company's transfer agent, Pacific Stock Transfer Company, is acting as the exchange agent for the Reverse Stock Split and will send stockholders of record holding their shares electronically in book-entry form a transaction notice indicating the number of shares of common stock held after the Reverse Stock Split. Stockholders who hold their shares through a broker, bank, or other nominee will have their positions adjusted to reflect the Reverse Stock Split, subject to their broker, bank, or other nominee's particular processes, and are not expected to be required to take any action in connection with the Reverse Stock Split.

Additional information regarding the Reverse Stock Split can be found in the Company's definitive proxy statement for the annual meeting of stockholders of the Company held on July 9, 2024, which was filed with the U.S. Securities and Exchange Commission on May 28, 2024, a copy of which is available at www.sec.gov and on the Company's website. 

About Movano Health
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health, maker of the Evie Ring (www.eviering.com), is developing a suite of purpose-driven healthcare solutions to bring medical-grade data to the forefront of wearables. Featuring modern and flexible form factors, Movano Health's devices offer an innovative approach to delivering trusted data to both customers and enterprises, capturing a comprehensive picture of an individual's health data and uniquely translating it into personalized and intelligent insights.

Movano Health's proprietary technologies and wearable medical device solutions will soon enable the use of data as a tool to proactively monitor and manage health outcomes across a number of patient populations that exist in healthcare. For more information on Movano Health, visit https://movanohealth.com/.

Forward Looking Statements
This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding plans with respect to the timing and impact of the Reverse Stock Split, the commercial launches of the Evie Ring and EvieMED Ring; our expectations regarding potential commercial opportunities; planned cost-cutting initiatives; anticipated FDA clearance decisions with respect to our products; expected future operating results; product development and features, product releases, clinical trials and regulatory initiatives; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/movano-health-announces-reverse-stock-split-302286792.html

SOURCE Movano

FAQ

What is the ratio of Movano Health's (MOVE) reverse stock split announced in October 2024?

Movano Health announced a 1-for-15 reverse stock split, effective October 29, 2024.

How many shares will Movano Health (MOVE) have outstanding after the October 2024 reverse split?

After the reverse split, Movano Health's outstanding shares will reduce from approximately 99.5 million to 6.6 million shares.

Why did Movano Health (MOVE) implement a reverse stock split in October 2024?

Movano Health implemented the reverse stock split to increase the bid price of its common stock to regain compliance with Nasdaq Capital Market's minimum bid price requirement for continued listing.

Movano Inc.

NASDAQ:MOVE

MOVE Rankings

MOVE Latest News

MOVE Stock Data

36.48M
5.49M
17.24%
13.46%
1.95%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
PLEASANTON